With 1 million new cases and 200,000 children dead each year, Tuberculosis (TB) is now the leading cause of death from infectious diseases for children of all ages globally (UNICEF). ImproViTB is among the first pediatric clinical studies in the Central African region aimed at improving the clinical outcome and quality of life of children with pulmonary tuberculosis through a standard antituberculosis treatment supplemented with vitamin D.
This project is lead by a consortium of research institutions and universities from 4 Central African countries (Republic of Congo, Democratic Republic of Congo, Cameroon and Gabon) and 3 European countries, coordinated by CANTAM (Prof. Francine Ntoumi), the Network of Excellence in clinical research for Central African region.

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

From 2003 at the forefront of supporting Sub-Saharan Africa’s response to poverty-related infectious diseases, EDCTP plays a key role also in the African response to Covid-19

The European & Developing Countries Clinical Trials Partnership (EDCTP) is a public-public partnership between countries in Europe and sub-Saharan Africa, supported by the European Union, which since 2003 has been

The way to build bridges instead of walls is still long.

The way to build bridges instead of walls is still long, but I am happy to have got European Union funding for this project. Africlinique project aims to increase the

INTEGRATION+

INTEGRATION+ is an implementation research focused on malaria in pregnancy, with the potential to change national health prevention policies to protect an additional 13 million pregnant women each year from